What is the efficacy of olaparib (Olaparib, Lipadro) combined with anlotinib?

Olaparib and anlotinib are both drugs that have attracted much attention in the anti-tumor field in recent years. Olaparib is an inhibitor of PARP (polymerase-adenylate diphosphate ribosylase), which can effectively inhibit the DNA repair mechanism of tumor cells. Anlotinib is a small molecule multi-target tyrosine kinase inhibitor that can inhibit VEGFR, PDGFR, FGFR, c-Kit and other kinases. It has the effect of anti-tumor angiogenesis and inhibiting tumor growth. The combined use of these two drugs theoretically has a stronger anti-tumor effect.

The combined use of olaparib and anlotinib can produce synergistic effects on efficacy. Olaparib makes tumor cells more sensitive to DNA damage by inhibiting DNA repair in tumor cells. Anlotinib further weakens the viability of tumor cells by inhibiting tumor angiogenesis and tumor cell growth. The combination of the two can more effectively inhibit the growth and spread of tumors.

In some clinical trials, the treatment regimen of olaparib combined with anlotinib has shown positive efficacy. For example, in a clinical trial of patients with advanced non-small cell lung cancer, the combination of these two drugs significantly prolonged progression-free survival (PFS) and overall survival (OS). At the same time, the combined treatment regimen also showed good safety and tolerability.

The treatment regimen of olaparib combined with anlotinib is suitable for patients with various types of tumors, especially those who are resistant to traditional chemotherapy drugs. However, when using this combination treatment regimen, you also need to pay attention to some possible adverse reactions, such as nausea, vomiting, diarrhea, etc. In addition, patients also need to undergo regular blood tests, liver and kidney function tests to ensure the safety of treatment.